Pfizer Inc (PFE)
Health Care · Pharmaceuticals · US stock · S&P 500 component
$30.42
▲ +0.57 (1.91%)
Fair valueFair
$30 −1.3% to fair value
$15fair band $26–$36$45
Day's range
$29.88 – $30.44
52-week range
$23.62 – $30.44
About Pfizer Inc
Pfizer is a global biopharmaceutical company that discovers, develops and supplies medicines and vaccines. Its portfolio includes the pneumococcal vaccine Prevnar, the blood thinner Eliquis, the cancer medicine Ibrance and a COVID vaccine and antiviral treatment, plus products in inflammation and rare disease. It also added cancer medicines through its purchase of Seagen. Customers are wholesalers, hospitals, pharmacies and governments.
Revenue of $63.7 billion over the last twelve months comes from patented medicines and vaccines. Revenue has changed at -14.8% a year across the last three years, a sharp decline. The operating margin is 10.8%, the business earns 4% on the capital invested in it, and net debt is 4.1 times EBITDA. The dividend yield is 5.7%. On the site's X-Ray Score it receives 31 out of 100.
Price chart
52-wk range $23.62 – $30.44Volume 28,682,254Daily, split-adjusted
Vitals
Market cap$173.4B
52-week range$23.62 – $30.44
Volume (last day)28,682,254
P/E (TTM)40.1
EBIT / EV yield3.0%
Free-cash-flow yield6.3%
Dividend yield5.7%
Revenue (TTM)$63.7B
Net income (TTM)$4.3B
Operating margin10.8%
Return on capital4.4%
Debt incl. leases$63.1B
Cash & securities$8.3B
Debt = borrowings plus lease liabilities. Cash & securities = cash, equivalents and short-term marketable securities (long-term securities are not counted, so net cash can be understated for companies that hold large long-term investments). Net debt = debt minus cash & securities. Source: latest SEC 10-Q/10-K. EBIT / EV yield = operating profit divided by market cap plus net debt.
Fair value estimate
$30middle half of models $25 – $34
Fair
−1.3% to fair value
Average of the 13 valuation models that pass our checks: multiples, discounted cash flow, dividend discount and earnings power value. A model more than 100% above or 60% below the price is left out as unrealistic. Model uncertainty is Medium, based on how far apart the models are. Undervalued or Overvalued means the gap to fair value is more than 17.5%.
Price $30
Undervalued < $26Fair $26 – $36Overvalued > $36
P/E multiple
$28
P/B multiple
$34
P/S multiple
$36
EV/EBITDA multiple
$29
EV/EBIT multiple
$20
EV/revenue multiple
$33
10-year DCF, EBITDA exit
$24
5-year DCF, EBITDA exit
$25
10-year DCF, revenue exit
$24
5-year DCF, revenue exit
$26
10-year DCF, growth exit · not used
$11
5-year DCF, growth exit · not used
$9
Dividend discount, stable
$42
Dividend discount, multi-stage
$44
Earnings power value
$25
Growth the price implies
23.0%/yr
A model estimate, not a price target or recommendation. Inputs: risk-free 5.13%, equity risk premium 4.30% (Damodaran). How it works.
What this means
Weak business, fairly priced
The price sits inside our fair-value band. A high score does not guarantee a good outcome; it shifts the odds a little. Use the checklist as a prompt for your own research.
Before you invest · decision checklist
Ticked boxes are filled in from our data; the rest are yours to answer.
The five-lens scan
Every score explained in one sentence, ranked against Health Care peers. Open a lens to see the numbers behind it.
Strong: 70 to 100Fair: 50 to 69Weak: under 50No score: not enough data
Valuation
Fair
52/100
Priced about in line with its sector.
See the numbers →
EBIT / EV yield3.0%
Free-cash-flow yield6.3%
Fair value vs price1.0×
Growth
Weak
4/100
Growing slower than most of its sector.
See the numbers →
Revenue growth (3y)-14.8%
EPS growth (3y)-37.1%
Growth consistency60%
Profitability
Weak
30/100
Earns lower returns on its capital than most peers.
See the numbers →
Return on invested capital4.4%
Operating margin10.8%
Gross profitability23.2%
Financial health
Weak
24/100
Balance sheet is more stretched than most peers.
See the numbers →
Piotroski F-Score5 / 9
Net debt / EBITDA4.1×
Interest cover2.6×
Dividends
Fair
50/100
Dividend is typical for its sector.
See the numbers →
Dividend yield5.7%
Dividends vs free cash flow89%
Dividend growth2.8%
Quarterly results: last 6 quarters
-7.8%
Mar '25
+10.3%
Jun '25
-5.9%
Sep '25
-1.2%
Dec '25
+5.4%
Mar '26
+2.6%
Jun '26
Revenue against the same quarter a year earlier. Latest quarter revenue $15.0B, diluted EPS $-0.04.
Compare with peers
ZTS Zoetis Inc.69 LLY ELI LILLY & Co62 BMY Bristol Myers Squibb C...60 JNJ Johnson & Johnson49Other Pharmaceuticals companies by X-Ray Score.
SWOT analysis: Pfizer Inc
Strengthsinside the company
- Free cash flow equals 6.3% of the market value, which funds dividends, buybacks or debt paydown.
Weaknessesinside the company
- Return on invested capital is only 4.4% (median 19.3% for industry peers), so the business earns little above its cost of capital.
- Operating margin of 10.8% is thin against 27.2% for industry peers.
- Revenue has fallen 14.8% a year over three years while industry peers grew 4.3%.
- Earnings per share have declined 37.1% a year over three years.
Opportunitiesvaluation and setting
- Price momentum is strong on the weekly and monthly signals (trends can reverse).
Threatsvaluation and setting
- Heavy debt makes profits sensitive to interest rates and refinancing conditions.
Written by fixed rules from the figures on this page and the peer table below: filings, our fair value, the sector climate and the price trend. It summarises the data, it is not a forecast or advice.
Compare PFE with peers and sector
Medians of 6 Pharmaceuticals peers and of 59 Health Care stocks in our universe.
Largest peers (X-Ray Score): LLY 62, JNJ 49, MRK 33, BMY 60, ZTS 69, VTRS 25.
| Metric | PFE | Peers | Sector |
|---|---|---|---|
| X-Ray Score (out of 100) | 31 | 55 | 49 |
| Valuation | 52 | 48 | 55 |
| Growth | 4 | 41 | 48 |
| Profitability | 30 | 58 | 51 |
| Financial health | 24 | 52 | 48 |
| Dividends | 50 | 56 | 52 |
Sector leaders: highest X-Ray Score in Health Care
PFE ranks #55 of 60 in Health Care and #6 of 7 in Pharmaceuticals by X-Ray Score. A higher score is stronger on our five pillars; it is a ranking of facts, not a forecast.
Green means better than the peer median, red worse (only where a higher or lower figure is clearly better). A dash means too few companies report the figure. P/E, EV/EBITDA and price changes are not graded: a different level is not good or bad by itself.
Factor ratings for PFE
Each factor is rated by where PFE stands among the 60 Health Care stocks in our universe.
Rating against the sector
Goodthe top third of these stocks
Averagethe middle third of these stocks
Badthe bottom third of these stocks
"Beats" is the share of those stocks it is ahead of.
Against its own history
The last columns set today's figure against the company's own median of its last five financial years:
▲ Betterbetter than its usual level
▼ Worseworse than its usual level
≈ In linewithin its usual range
For valuation factors Good means cheaper than most of the sector and Better means cheaper than usual for this company, which is not the same as a bargain.
In total: 5 Good · 4 Average · 14 Bad of 23
Growth: 0 · 0 · 3
Profitability: 1 · 0 · 4
Financial strength: 0 · 1 · 3
Valuation: 2 · 2 · 1
Cash flow: 2 · 1 · 1
Efficiency: 0 · 0 · 2
| Factor | PFE | Rating | Sector median | Own 5-year median | Against own history |
|---|---|---|---|---|---|
| Growth | |||||
| Revenue growth, 3 years a year | −14.8% | Bad beats 3% | +5.5% | – | – |
| Revenue growth, last year | −1.6% | Bad beats 4% | +7.1% | +6.8% | ▼ Worse |
| EPS growth, 3 years a year | −37.1% | Bad beats 1% | +5.0% | – | – |
| Profitability | |||||
| Gross margin | 73.2% | Good beats 81% | 65.0% | 66.1% | ▲ Better |
| Operating margin | 10.8% | Bad beats 31% | 16.4% | 17.5% | ▼ Worse |
| Net margin | 6.8% | Bad beats 30% | 11.1% | 12.6% | ▼ Worse |
| Return on invested capital | 4.4% | Bad beats 16% | 12.2% | – | – |
| Return on equity | 5.1% | Bad beats 16% | 13.7% | 9.1% | ▼ Worse |
| Financial strength | |||||
| Net debt / EBITDA | 4.1x | Bad beats 15% | 2.0x | 2.9x | ▼ Worse |
| Interest cover | 2.6x | Bad beats 11% | 9.4x | 3.8x | ▼ Worse |
| Current ratio | 1.27 | Average beats 34% | 1.52 | 1.17 | ≈ In line |
| Piotroski F-score | 5 / 9 | Bad beats 25% | 6 / 9 | – | – |
| Valuation | |||||
| P/E ratio | 40.0x | Bad beats 27% | 28.2x | 18.3x | ▼ Worse |
| Price / book | 2.0x | Good beats 85% | 3.7x | 1.8x | ≈ In line |
| Price / sales | 2.7x | Average beats 61% | 3.7x | 2.8x | ≈ In line |
| EV / EBITDA | 16.9x | Average beats 55% | 17.6x | 11.4x | ▼ Worse |
| Free cash flow yield | 6.3% | Good beats 74% | 4.4% | 6.5% | ≈ In line |
| Cash flow | |||||
| Free cash flow margin | 17.2% | Average beats 54% | 16.3% | 15.5% | ▲ Better |
| Cash from operations / net income | 3.09 | Good beats 93% | 1.61 | 1.51 | ▲ Better |
| Free cash flow growth, 3 years a year | −29.6% | Bad beats 3% | +4.3% | – | – |
| Accruals (lower is better) | −4.5% | Good beats 69% | −3.9% | – | – |
| Efficiency | |||||
| Inventory turnover | 1.7x | Bad beats 20% | 2.9x | 2.4x | ▼ Worse |
| Days sales outstanding | 72 days | Bad beats 27% | 62 days | 66 days | ≈ In line |
These ratings compare companies with each other and describe the past; they are not a forecast, a recommendation or part of the X-Ray Score. A factor is left out when its data is missing or meaningless (for example a P/E on negative earnings). A dash in the history columns means fewer than three usable years.
Fundamentals checklist
● 2 Good · ● 3 Average · ● 11 BadCash quality
Earnings backed by cashGood
Free-cash-flow yieldGood
Risk models
Altman Z''Average
Piotroski F-ScoreBad
Growth
EPS growth (3y)Bad
Free-cash-flow growth (3y)Bad
Revenue growth (3y)Bad
Growth consistencyBad
Balance sheet
Current ratioAverage
Net debt / EBITDABad
Interest coverBad
Valuation
Fair value vs priceAverage
EBIT / EV yieldBad
Profitability
Return on invested capitalBad
Operating marginBad
Gross profitabilityBad
Each check is graded against the company's sector, not a fixed number. Checklist score 30/100.
Financials
| FY21 | FY22 | FY23 | FY24 | FY25 | |
|---|---|---|---|---|---|
| Revenue | $81.3B | $101.2B | $59.6B | $63.6B | $62.6B |
| Operating income | $25.6B | $36.0B | $3.3B | $11.1B | $10.2B |
| Net income | $22.0B | $31.4B | $2.1B | $8.0B | $7.8B |
| Operating cash flow | $32.6B | $29.3B | $8.7B | $12.7B | $11.7B |
| Operating margin | 31.5% | 35.5% | 5.5% | 17.5% | 16.3% |
| Free cash flow | $29.9B | $26.0B | $4.8B | $9.8B | $9.1B |
| Diluted EPS | $3.85 | $5.47 | $0.37 | $1.41 | $1.36 |
Fiscal years, from SEC filings.
Technical summary
Daily
Bullish
12 bullish · 0 neutral · 4 bearish
Weekly
Strongly bullish
11 bullish · 0 neutral · 1 bearish
Monthly
Strongly bullish
7 bullish · 1 neutral · 0 bearish
Moving averages (daily)
| SMA 10 | 29.31 | Bullish |
| EMA 10 | 29.44 | Bullish |
| SMA 20 | 28.72 | Bullish |
| EMA 20 | 28.93 | Bullish |
| SMA 50 | 28.23 | Bullish |
| EMA 50 | 28.07 | Bullish |
| SMA 100 | 26.52 | Bullish |
| EMA 100 | 27.18 | Bullish |
| SMA 200 | 26.15 | Bullish |
| EMA 200 | 26.23 | Bullish |
Oscillators (daily)
| RSI (14) | 72.19 | Bearish |
| MACD (12, 26) | 0.58 | Bullish |
| Momentum (12) | 10.62 | Bullish |
| Stochastic %K (14) | 99.40 | Bearish |
| Williams %R (14) | -0.60 | Bearish |
| CCI (20) | 148.3 | Bearish |
Pivot points (classic, last session)
S3 29.49 | S2 29.69 | S1 30.05 | Pivot 30.25 | R1 30.61 | R2 30.81 | R3 31.17 |
Signals describe what the chart is doing, not what to do. Moving averages: price above the average is bullish. Oscillators use the usual thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20; MACD and momentum above zero are bullish). Weekly and monthly views use closing prices only.
Dividends
Paid, last 12 months
1.72 USD
Yield on today's price
5.65%
Frequency
Quarterly
Next ex-dividend date
6 Nov 2026
| Ex-dividend date | Amount per share |
|---|---|
| (upcoming) | 0.4300 |
| 0.4300 | |
| 0.4300 | |
| 0.4300 | |
| 0.4300 | |
| 0.4300 | |
| 0.4300 | |
| 0.4300 | |
| 0.4200 | |
| 0.4200 | |
| 0.4200 | |
| 0.4200 |
Ex-dividend dates and amounts from EODHD. Shown as declared, before tax.
ETFs that hold PFE
| ETF | Share of the fund |
|---|---|
| FDL First Trust Morningstar Dividend Leade... | 5.91% |
| PPH VanEck Pharmaceutical | 4.51% |
| HDV iShares Core High Dividend | 4.27% |
| IHE iShares U.S. Pharmaceuticals | 3.96% |
| SPHD Invesco S&P 500 High Dividend Low Vola... | 2.98% |
| XLV Health Care Select Sector SPDR | 2.39% |
| PEY Invesco High Yield Equity Dividend Ach... | 2.39% |
| VHT Vanguard Health Care | 2.35% |
The eight funds with the largest weight in PFE among the ETFs we cover, from each fund's latest SEC Form N-PORT (quarter-end positions, so they can be months old). All ETFs.
PFE stock splits
PFE has split its stock 4 times since 1991. The latest was a 3-for-1 split on 1 Jul 1999.
Full PFE stock split history →PFE SEC filings
10-QSEC EDGAR
Quarterly report
8-KSEC EDGAR
Results of operations
8-KSEC EDGAR
Regulation FD disclosure
8-KSEC EDGAR
Director or officer change
10-QSEC EDGAR
Quarterly report
8-KSEC EDGAR
Results of operations
8-KSEC EDGAR
Shareholder vote results
DEF 14ASEC EDGAR
Proxy statement
Where the numbers come from
Statements SEC EDGAR filings (10-K, 10-Q), quarters derived from year-to-date figures.
Prices end-of-day closes, split-adjusted.
Industry inputs beta, multiples and equity risk premium from Damodaran Online (NYU Stern).
StocksXray is for education only and is not financial advice. Scores and fair values are model estimates from public filings and carry uncertainty.